☆ 4.2 Article

Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin

PRIMARY CARE DIABETES (2010)

期刊

PRIMARY CARE DIABETES

卷 4, 期 2, 页码 113-117

出版社

ELSEVIER SCI LTD

DOI: 10.1016/j.pcd.2010.04.001

关键词

Type 2 diabetes; DTSQ; IWQOL-Lite; Liraglutide; Treatment satisfaction

类别

Endocrinology & Metabolism Primary Health Care

资金

Novo Nordisk
Novo Nordisk Inc.
National Institute for Health Research [NF-SI-0508-10272] Funding Source: researchfish

向作者/读者索取更多资源

Protocol

Reagent

摘要

Patient-reported outcomes for liraglutide or glimepiride on metformin were investigated. Patients' treatment satisfaction on liraglutide was higher than with metformin alone and comparable with glimepiride + metformin. Patients perceived lower frequency of hypoglycaemia than glimepiride + metformin and lower frequency of hyperglycaemia than metformin. Impact of weight on quality of life did not differ. (C) 2010 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Endocrinology & Metabolism

Changes in Treatment Satisfaction Over 3 Years in Patients With Type 2 Diabetes After Initiating Second-line Treatment

Tomoya Mita, Naoto Katakami, Mitsuyoshi Takahara, Masaru Kawashima, Fumitaka Wada, Hiroki Akiyama, Naru Morita, Yoko Kidani, Toshitaka Yajima, Iichiro Shimomura, Hirotaka Watada

Summary: This study examined the change in treatment satisfaction and factors affecting this change among patients with early-stage type 2 diabetes mellitus in Japan.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Factors associated with gastrointestinal side effects after liraglutide treatment for type 2 diabetes

Hao Wu, Zongshi Lu, Runyao Chen, Quanfang Cai, Miaomiao Wang, Liting Zhang, Zhiming Zhu

Summary: This study identified AGI use, concomitant gastrointestinal diseases, higher TSH levels, and female sex as independent risk factors for the gastrointestinal side effects of liraglutide treatment in patients with T2DM. Further research is needed to understand these interactions.

FRONTIERS IN ENDOCRINOLOGY (2023)

添加到收藏夹

Article Endocrinology & Metabolism

Pharmacoeconomic analysis (CER) of Dulaglutide and Liraglutide in the treatment of patients with type 2 diabetes

Yu Su, Shuo Zhang, Zezhen Wu, Weiting Liu, Jingxian Chen, Feiying Deng, Fengwu Chen, Dan Zhu, Kaijian Hou

Summary: This study evaluated the treatment effect and pharmacoeconomic value of Dulaglutide in women with type 2 diabetes. The results showed that Dulaglutide and Liraglutide both reduced blood glucose levels, improved biochemical index, and HOMA-IR levels in women with type 2 diabetes. However, Dulaglutide was found to be more cost-effective and safer.

FRONTIERS IN ENDOCRINOLOGY (2023)

添加到收藏夹

Review Medicine, General & Internal

Type 2 diabetes

Ehtasham Ahmad, Soo Lim, Roberta Lamptey, David R. Webb, Melanie J. Davies

Summary: Type 2 diabetes accounts for nearly 90% of global diabetes cases, with an increasing number of affected individuals, particularly among young people. Early detection and proactive management are crucial for preventing complications and reducing mortality. Technology and precision medicine offer potential improvements to treatment outcomes but face significant barriers.

LANCET (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes

Damien Denimal, Victoria Bergas, Jean-Paul Pais-de-Barros, Isabelle Simoneau, Laurent Demizieux, Patricia Passilly-Degrace, Benjamin Bouillet, Petit Jean-Michel, Alexia Rouland, Amandine Bataille, Laurence Duvillard, Bruno Verges

Summary: The study investigates the effects of the GLP-1 receptor agonist liraglutide on the levels of dihydroceramides (DhCer) and ceramides (Cer) in type 2 diabetes (T2D) patients. Results show that liraglutide reduces plasma levels of DhCer and Cer species, which may contribute to the cardiovascular benefits observed. Additionally, the decrease in plasma DhCer levels is independently associated with the reduction in liver fat content and insulin resistance.

CARDIOVASCULAR DIABETOLOGY (2023)

添加到收藏夹

Article Medicine, General & Internal

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

W. Timothy Garvey, Juan P. Frias, Ania M. Jastreboff, Carel W. le Roux, Naveed Sattar, Diego Aizenberg, Huzhang Mao, Shuyu Zhang, Nadia N. Ahmad, Mathijs C. Bunck, Imane Benabbad, Xiaotian M. Zhang

Summary: This study assessed the efficacy and safety of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, for weight management in individuals with obesity and type 2 diabetes. The results showed that once-weekly tirzepatide treatment significantly reduced bodyweight and achieved clinically meaningful weight loss, with a safety profile comparable to other weight management therapies.

LANCET (2023)

添加到收藏夹

Article Multidisciplinary Sciences

Effect of liraglutide on expression of inflammatory genes in type 2 diabetes

Emilie H. Zobel, Rasmus S. Ripa, Bernt J. von Scholten, Viktor Rotbain Curovic, Andreas Kjaer, Tine W. Hansen, Peter Rossing, Joachim Storling

Summary: Liraglutide has been found to exert anti-inflammatory effects in the peripheral blood mononuclear cells of individuals with type 2 diabetes, with no significant presence of GLP-1 receptor expression. Further research is needed to clarify the indirect effects of liraglutide on PBMC gene expression and establish the anti-inflammatory potential of GLP-1 receptor agonists.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Urinary Proteome Differences in Patients with Type 2 Diabetes Pre and Post Liraglutide Treatment

Mohamed Rafiullah, Hicham Benabdelkamel, Afshan Masood, Aishah A. Ekhzaimy, Mohthash Musambil, Salini Scaria Joy, Assim A. Alfadda

Summary: This study investigated changes in the urinary proteomic profile of diabetic patients before and after liraglutide treatment using 2D-DIGE MALDI TOF mass spectrometry. The study found that 32 proteins showed significant changes after liraglutide treatment, with upregulation of albumin, serotransferrin, metallothionein-2, keratins K1 and K10. These findings suggest the renoprotective effect of liraglutide and highlight the need for further research on its molecular mechanisms.

CURRENT ISSUES IN MOLECULAR BIOLOGY (2023)

添加到收藏夹

Article Endocrinology & Metabolism

Association between use of liraglutide and liver fibrosis in patients with type 2 diabetes

Yijiong Tan, Qin Zhen, Xiaoying Ding, Tingting Shen, Fang Liu, Yufan Wang, Qidi Zhang, Renkun Lin, Lili Chen, Yongde Peng, Nengguang Fan

Summary: This study found that the use of Liraglutide treatment is associated with a reduced risk of liver fibrosis in patients with type 2 diabetes.

FRONTIERS IN ENDOCRINOLOGY (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Metabolic remodeling of glycerophospholipids acts as a signature of dulaglutide and liraglutide treatment in recent-onset type 2 diabetes mellitus

Juan Du, Liuqing Xi, Zhongxiao Zhang, Xiaoxu Ge, Wenyi Li, Wenfang Peng, Xiaohong Jiang, Wen Liu, Nan Zhao, Xingyun Wang, Xirong Guo, Shan Huang

Summary: This study investigated the effects of newly developed long-acting GLP-1RAs, such as dulaglutide and liraglutide, on metabolic remodeling in patients with recent-onset T2D. Through untargeted metabolomics analysis, significant changes in metabolites were identified in T2D patients compared to the control group. Treatment with dulaglutide and liraglutide led to the regulation of different metabolites, particularly in glycerophospholipid metabolism, and enriched the insulin resistance pathway and type 2 diabetes mellitus.

FRONTIERS IN ENDOCRINOLOGY (2023)

添加到收藏夹

Article Endocrinology & Metabolism

Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes

Marja-Riitta Taskinen, Elias Bjornson, Niina Matikainen, Sanni Soderlund, Kirsi H. Pietilainen, Mari Ainola, Antti Hakkarainen, Nina Lundbom, Johannes Fuchs, Annika Thorsell, Linda Andersson, Martin Adiels, Chris J. Packard, Jan Boren

Summary: In subjects with type 2 diabetes, liraglutide demonstrated positive effects on postprandial apoB48 metabolism, including reducing apoB48 synthesis, improving chylomicron size, and decreasing direct clearance of chylomicrons, as well as lowering VLDL1-triglyceride secretion. The impact of liraglutide on insulin sensitivity altered certain associations related to chylomicron-apoB48 production and particle size, ultimately contributing to decreased generation of remnant lipoproteins.

DIABETES OBESITY & METABOLISM (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Glycemia and Gluconeogenesis With Metformin and Liraglutide: A Randomized Trial in Youth-onset Type 2 Diabetes

Katrina B. Dietsche, Sheela N. Magge, Sydney A. Dixon, Faith S. Davis, Andrea Krenek, Aruba Chowdhury, Lilian Mabundo, Michael Stagliano, Amber B. Courville, Shanna Yang, Sara Turner, Hongyi Cai, Kannan Kasturi, Arthur S. Sherman, Joon Ha, Eileen Shouppe, Mary Walter, Peter J. Walter, Kong Y. Chen, Robert J. Brychta, Cody Peer, Yi Zeng, William Figg, Fran Cogen, D. Elizabeth Estrada, Shaji Chacko, Stephanie T. Chung

Summary: This study evaluated the glucose-lowering mechanisms of metformin and liraglutide in African American youth with youth-onset type 2 diabetes. The results showed that both metformin and liraglutide improved glycemic control but did not suppress high rates of gluconeogenesis. Novel therapies targeting beta-cell function and elevated rates of gluconeogenesis are needed for youth-onset type 2 diabetes.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2023)

添加到收藏夹

Article Multidisciplinary Sciences

The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes

Suvanjaa Sivalingam, Emil List Larsen, Daniel H. van Raalte, Marcel H. A. Muskiet, Mark M. Smits, Lennart Tonneijck, Jaap A. Joles, Bernt Johan von Scholten, Emilie Hein Zobel, Frederik Persson, Trine Henriksen, Lars Jorge Diaz, Tine W. Hansen, Henrik Enghusen Poulsen, Peter Rossing

Summary: This post-hoc analysis of two clinical trials showed that 12 weeks of treatment with liraglutide or sitagliptin did not have a beneficial effect on oxidatively generated modifications of nucleic acid in individuals with type 2 diabetes.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Review Medicine, Research & Experimental

Pharmacological treatment of hyperglycemia in type 2 diabetes

Simeon I. Taylor, Zhinous Shahidzadeh Yazdi, Amber L. Beitelshees

Summary: Diabetes mellitus is a significant public health issue, with pharmacotherapy aiming to prevent complications. Clinical trials have shown that intensive glycemic control can slow the progression of complications, with some drugs also demonstrating cardiovascular benefits and slowed progression of diabetic kidney disease.

JOURNAL OF CLINICAL INVESTIGATION (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Dissolving microneedle-assisted long-acting Liraglutide delivery to control type 2 diabetes and obesity

Morteza Rabiei, Soheila Kashanian, Gholamreza Bahrami, Hossein Derakhshankhah, Ebrahim Barzegari, Seyedeh Sabereh Samavati, Steven J. P. McInnes

Summary: Integrating nanoparticles with dissolving microneedles creates a promising non-invasive drug delivery device that provides sustained release and eliminates the need for subcutaneous injection, while also enhancing mechanical strength. The flexible backing layer obtained through blending of PVP and PVA, maintains the native secondary structure of the encapsulated drug according to CD analysis.

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Perceptions of Barriers to Effective Obesity Care: Results from the National ACTION Study

Lee M. Kaplan, Angela Golden, Kimberly Jinnett, Ronette L. Kolotkin, Theodore K. Kyle, Michelle Look, Joseph Nadglowski, Patrick M. O'Neil, Thomas Parry, Kenneth J. Tomaszewski, Boris Stevenin, Soren Kruse Lilleore, Nikhil V. Dhurandhar

OBESITY (2018)

添加到收藏夹

Article Surgery

Patient-Reported Outcome Measures 2 Years After Standard and Distal Gastric Bypass-a Double-Blind Randomized Controlled Trial

Marius Svanevik, Hilde Risstad, Tor-Ivar Karlsen, Jon A. Kristinsson, Milada Cvancarova Smastuen, Ronette L. Kolotkin, Torgeir T. Sovik, Rune Sandbu, Tom Mala, Joran Hjelmesaeth

OBESITY SURGERY (2018)

添加到收藏夹

Article Surgery

12-year trajectory of health-related quality of life in gastric bypass patients versus comparison groups

Ronette L. Kolotkin, Jaewhan Kim, Lance E. Davidson, Ross D. Crosby, Steven C. Hunt, Ted D. Adams

SURGERY FOR OBESITY AND RELATED DISEASES (2018)

添加到收藏夹

Article Surgery

Eating self-efficacy as predictor of long-term weight loss and obesity-specific quality of life after sleeve gastrectomy: A prospective cohort study

Tone Nygaard Flolo, Grethe S. Tell, Ronette L. Kolotkin, Anny Aasprang, Tone M. Norekval, Villy Vage, John R. Andersen

SURGERY FOR OBESITY AND RELATED DISEASES (2019)

添加到收藏夹

Article Surgery

Changes in Sexual Functioning in Women and Men in the 5 Years After Bariatric Surgery

Kristine J. Steffen, Wendy C. King, Gretchen E. White, Leslee L. Subak, James E. Mitchell, Anita P. Courcoulas, David R. Flum, Gladys Strain, David B. Sarwer, Ronette L. Kolotkin, Walter Pories, Alison J. Huang

JAMA SURGERY (2019)

添加到收藏夹

Article Endocrinology & Metabolism

Confirmatory psychometric evaluations of the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT)

Ronette L. Kolotkin, Valerie S. L. Williams, Lisa von Huth Smith, Henrik Hjorth Meincke, Shanshan Qin, Nicole Williams, Sheri E. Fehnel

Summary: The IWQOL-Lite-CT, developed for assessing weight-related physical and psychosocial functioning, was confirmed for structure, reliability, and validity through two clinical trials. It demonstrated strong ability to detect change, discriminate between groups, and had responder thresholds ranging from 13.5 to 16.6 across composite scores.

CLINICAL OBESITY (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Effect of once-weekly subcutaneous semaglutide 2.4 mg on weight- and health-related quality of life in an East Asian population: Patient-reported outcomes from the STEP 6 trial

Ronette L. Kolotkin, Ole Kleist Jeppesen, James Baker-Knight, Sang Yeoup Lee, Asako Tokita, Takashi Kadowaki

Summary: The study examined the impact of semaglutide 2.4 and 1.7 mg versus placebo on weight-related quality of life (WRQOL) and health-related quality of life (HRQOL) in individuals from East Asia. The results showed that semaglutide 2.4 mg significantly improved WRQOL and HRQOL scores, particularly in the psycho-social and physical domains. However, semaglutide 1.7 mg did not show significant effects on HRQOL.

CLINICAL OBESITY (2023)

添加到收藏夹

Article Endocrinology & Metabolism

Validation of a new measure of quality of life in obesity trials: Impact of Weight on Quality of Life-Lite Clinical Trials Version

Ronette L. Kolotkin, Valerie S. L. Williams, Claire M. Ervin, Nicole Williams, Henrik H. Meincke, Shanshan Qin, Lisa von Huth Smith, Sheri E. Fehnel

CLINICAL OBESITY (2019)

添加到收藏夹

Article Endocrinology & Metabolism

A call to action to inform patient-centred approaches to obesity management: Development of a disease-illness model

John Fastenau, Ronette L. Kolotkin, Ken Fujioka, Maria Alba, William Canovatchel, Shana Traina

CLINICAL OBESITY (2019)

添加到收藏夹

Article Public, Environmental & Occupational Health

Effects of a physical activity intervention on schoolchildren's health-related quality of life: The active smarter kids (ASK) cluster-randomized controlled trial

Geir Kare Resaland, Eivind Aadland, Vegard Fusche Moe, Ronette L. Kolotkin, Sigmund A. Anderssen, John Roger Andersen

PREVENTIVE MEDICINE REPORTS (2019)

添加到收藏夹

Review Endocrinology & Metabolism

A review of systematic reviews on the effects of patient-reported outcome monitoring with clinical feedback systems on health-related quality of life-implications for a novel technology in obesity treatment

P. A. Hegland, A. Aasprang, S. Hjelle Oygard, S. Nordberg, R. Kolotkin, C. Moltu, G. S. Tell, J. R. Andersen

CLINICAL OBESITY (2018)

添加到收藏夹

Article Endocrinology & Metabolism

Improvements in health-related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity

R. L. Kolotkin, B. Gabriel Smolarz, H. H. Meincke, K. Fujioka

CLINICAL OBESITY (2018)

添加到收藏夹

Article Endocrinology & Metabolism

Health-related quality of life in randomized controlled trials of lorcaserin for obesity management: what mediates improvement?

R. L. Kolotkin, R. D. Crosby, Z. Wang

CLINICAL OBESITY (2017)

添加到收藏夹

Review Endocrinology & Metabolism

A systematic review of reviews: exploring the relationship between obesity, weight loss and health-related quality of life

R. L. Kolotkin, J. R. Andersen

CLINICAL OBESITY (2017)

添加到收藏夹

Article Endocrinology & Metabolism

Development of a clinical trials version of the Impact of Weight on Quality of Life-Lite questionnaire (IWQOL-Lite Clinical Trials Version): results from two qualitative studies

R. L. Kolotkin, C. M. Ervin, H. H. Meincke, L. Hojbjerre, S. E. Fehnel

CLINICAL OBESITY (2017)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.